Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: June 24, 2013
Subject: Announcement of data from five Phase III clinical studies (Harmony 1 to 5) for albiglutide, an investigational once-weekly treatment for type 2 diabetes.
Key Financial Metrics
This filing is a clinical data announcement and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The filing details the results of the Harmony Phase III program involving over 5,000 patients. Key findings include:
- Harmony 1: Albiglutide showed a statistically significant HbA1c reduction (-0.8%) vs. placebo in patients on pioglitazone. 44% of albiglutide patients achieved HbA1c <7% vs. 15% on placebo.
- Harmony 2: Both 30mg and 50mg doses showed significant HbA1c reductions vs. placebo in drug-naive patients. No severe hypoglycaemia reported.
- Harmony 3: Albiglutide demonstrated superior HbA1c reduction vs. placebo, sitagliptin, and glimepiride over 104 weeks. Significant weight loss observed vs. glimepiride.
- Harmony 4: Albiglutide was non-inferior to insulin glargine in HbA1c reduction. Patients on albiglutide lost weight (-1.1kg) while those on insulin gained weight (+1.6kg).
- Harmony 5: Albiglutide was superior to placebo but did not meet the non-inferiority margin versus pioglitazone.
Outlook, Risks, and Unusual Items
Regulatory Status: Albiglutide is not approved for use anywhere in the world but is undergoing regulatory review in the US and EU.
Safety Profile: The most commonly reported adverse reactions were gastrointestinal complaints (nausea, diarrhoea) and injection site reactions. Rates of severe hypoglycaemia were low (0.4% to 1%) across studies.
Forward-Looking Statements: GSK cautions that projections are subject to risks and uncertainties that may cause actual results to differ materially.
Investor Verification Checklist
- Verify the regulatory timeline for albiglutide approval in the US and EU.
- Confirm the commercial potential of albiglutide given the failure to meet non-inferiority against pioglitazone in Harmony 5.
- Review the full safety data regarding gastrointestinal adverse events and injection site reactions.
- Check for subsequent filings regarding the Harmony 8 study results mentioned in the text.